摘要
目的比较奥氮平联合昂丹司琼与单用昂丹司琼预防非小细胞肺癌(NSCLC)化疗所致恶心呕吐(CINV)的效果。方法 84例NSCLC患者随机分为研究组(42例)及对照组(42例),研究组和对照组均在化疗前30min给予静脉滴注昂丹司琼8mg,研究组自化疗第1天早晨开始口服奥氮平10mg,连用8d,评价化疗第1周期的止吐效果。结果研究组和对照组急性呕吐的发生率分别为33.33%(14/42)和54.76%(23/42),差异有统计学意义,P<0.05;迟发性呕吐的发生率分别为16.67%(7/42)和47.62%(20/42),差异有统计学意义,P<0.01。结论奥氮平联合昂丹司琼与单用昂丹司琼相比,奥氮平联合昂丹司琼对于预防NSCLC化疗所致恶心呕吐有更好的效果,尤其是对迟发型恶心呕吐效果更为显著。
Objective To compare the effectiveness of olanzapine combined with ondansetron and single use of ondansetron in prevention of chemotherapy-induced nausea and vomiting（CINV） of non-small cell lung cancer （NSCLC）. Methods 84 NSCLC patients were randomly divided into the control group and the test group, 42 patients in each group. 30 min before chemotherapy, both of the two groups were intravenous injection of ondansetron 8 mg. From the first day morning of chemotherapy, the test group were given olanzapine 10 mg for 8 days, then the antiemetic effect of the first cycles of chemotherapy was evaluated. Result Acute vomiting rates of the test group and control group were 33.33% （14/42） and 54.76% （23/42） respectively, there was statistical significance （ P 〈 0.05 ） ; Delayed vomiting rate were 16.67% （7/42） and 47.62% （20/42） respectively, there was statistical significance （ P 〈 0. 01 ）. Conclusion Olanzapine combined with ondansetron compared with single use of ondansetron, olanzapine combined with ondansetron has better effect for prevention CINV of NSCLC, especially for the delayed nausea and vomiting, the effect is much more obvious.
出处
《中华肺部疾病杂志（电子版）》
CAS
2012年第6期12-14,共3页
Chinese Journal of Lung Diseases(Electronic Edition)
关键词
非小细胞肺癌
奥氮平
昂丹司琼
化疗
恶心呕吐
Non-small cell lung cancer
Olanzapine
Ondansetron
Chemotherapy
Naused and vomiting
